Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc. for possible violations of federal securities laws and unlawful business practices [1][3]. Company Investigation - Semler Scientific Inc. disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding reimbursement claims related to its QuantaFlo device [3]. - The company has faced multiple requests for information from the DOJ over the years, with the most recent being in April 2023 [3]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, and there is a risk of a civil False Claims Act lawsuit being filed against Semler [3]. Stock Performance - Following the news of the DOJ investigation and potential lawsuit, Semler's stock price fell by $4.03, from $42.92 on February 28, 2025, to $38.89 on March 3, 2025 [3].

Core Viewpoint - The Department of Justice is investigating UnitedHealth for allegedly encouraging staff to make specific diagnoses that would lead to higher Medicare payments, particularly under the Medicare Advantage program [1][6]. Investigation Details - The investigation involves inquiries from the Justice Department, FBI, and Health and Human Services regarding patient testing, diagnostic procedures, and the process of sending nurses to patients' homes [2]. - Former employees reported that investigators asked about training related to making diagnoses and the methods used to contact patients for testing [4][8]. Company Response - UnitedHealth maintains that it supports the integrity of its Medicare Advantage business and welcomes regular reviews of its practices [3]. - The company criticized the Wall Street Journal for what it perceives as a biased narrative against Medicare Advantage, claiming reliance on incomplete data [3][4]. Diagnostic Practices - Former doctors indicated that the focus was on coding practices, specifically how diagnosis codes are submitted to Medicare for payments [5]. - Investigators inquired about bonuses for doctors reviewing potential diagnoses suggested by UnitedHealth [7]. Software and Tools - The investigation also looked into the "diagnosis cart" feature of UnitedHealth's software, which suggests potential medical conditions to nurses [11]. - UnitedHealth argues that its diagnostic practices are aimed at early disease detection and plans to implement independent third-party oversight for these practices [8]. Previous Investigations - A separate decade-long effort by the Justice Department to recover alleged Medicare overpayments from UnitedHealth was unsuccessful [10].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Semler Scientific Inc. and its officers or directors [1] Group 1: Legal Investigation - Pomerantz LLP is representing investors of Semler Scientific Inc. in an investigation regarding possible securities fraud [1] - The investigation follows Semler's disclosure of a risk related to a potential complaint from the U.S. Department of Justice regarding the company's reimbursement claims for its QuantaFlo device [3] Group 2: Financial Impact - Following the news of the investigation and the DOJ's involvement, Semler's stock price dropped by $4.03, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential breaches of fiduciary duty by the Board of Directors and senior management of Semler Scientific Inc. related to securities fraud allegations [1][2]. Investigation Details - The investigation focuses on whether certain officers and/or directors of Semler have engaged in securities fraud [2]. - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding claims for reimbursement related to the QuantaFlo device [3]. - Subsequent requests for information from the DOJ occurred in February 2019, December 2021, April 2022, and April 2023, with unsuccessful settlement discussions taking place in February 2025 [3]. - There is a risk that the DOJ may file a complaint in a civil False Claims Act lawsuit seeking damages against Semler [3]. Firm Background - Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation across state and federal courts [3]. - The firm is recognized for its expertise in shareholder and class litigation, having been appointed to significant positions in complex securities and multi-district litigation by the courts [3].

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud by the company and its officers and/or directors [1][2]. Investigation Details - The investigation is focused on whether Semler and certain officers and/or directors have engaged in securities fraud [2]. - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 concerning claims for reimbursement related to the QuantaFlo device [3]. - The company has received multiple requests for information from the DOJ over the years, with the most recent being in April 2023 [3]. - In February 2025, Semler engaged in unsuccessful settlement discussions with the DOJ, which raises the risk of a potential civil False Claims Act lawsuit seeking damages [3]. Firm Background - Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation in various courts across the United States [3]. - The firm is recognized for its expertise in shareholder and class litigation, having been appointed to significant positions in complex securities and multi-district litigation by the courts [3].